Stephen Charles Inglis

TL;DR: Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.

TL;DR: The construction and characterisation of a recombinant vaccinia virus designed to express modified forms of the E6 and E7 proteins from HPV16 and HPV18, the viruses most commonly associated with cervical cancer are described.

TL;DR: There was a trend toward reduced recurrence following therapeutic vaccination of animals already infected with HSV-2, and DISC HSV vaccination, therefore, offers an effective route for control of HSV disease.

TL;DR: In all cases, vaccination with the inactivated virus preparation provided substantially less protection from disease than the live DISC HSV-1 by the equivalent route, which was accompanied by significantly lower challenge virus titres in vaginal swabs collected from the vaccinated animals.

TL;DR: A mutant virus for use as a vaccine was proposed in this article, where the genome of the virus is defective in respect of a gene essential for the production of infectious virus and the mutant virus can be produced in a recombinant host cell which expresses a gene complementing the defect.